Natera, Inc. (NTRA) News
Follow Natera, Inc. (NTRA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 39 public stories across 27 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Natera Shares Slide on Wider-Than-Expected Loss, CEO Transition
By Natalie WegerShares of Natera slumped after the company posted a wider-than-expected loss in its latest quarter and said its chief executive is stepping down.The stock declined 20% to $292.47 in after-hours trading on
EQUITY | Nov 05, 2026, 10:51 PM UTC
M
Natera’s Third-Quarter Loss Narrows; FY26 Revenue Outlook Raised
Natera said its third-quarter loss narrowed year over year, driven largely by strong revenue growth from higher testing volumes and improved average selling prices. It raised its full-year 2026 revenue outlook.
EQUITY | Nov 05, 2026, 10:49 PM UTC
M
Natera’s Q3 Loss Narrows as Revenue Rises 34.1%
Natera reported a third-quarter loss, compared with a loss a year earlier. Revenue rose 34.1% to $793.981 million.
EQUITY | Nov 05, 2026, 09:52 PM UTC
M
Natera Q3 Revenue Beats Estimates, Raises 2026 Outlook
EQUITY | Nov 05, 2026, 09:46 PM UTC
M
Natera Names Solomon Moshkevich CEO
EQUITY | Nov 05, 2026, 09:29 PM UTC
M
Natera Q3 2026 Earnings Call Begins
Natera's quarterly earnings call has begun.
EQUITY | Nov 05, 2026, 09:27 PM UTC
M
Natera Reports Third-Quarter 2026 Financial Results
Natera reported total revenue of $794.0 million for the third quarter ended September 30, 2026.
EQUITY | Nov 05, 2026, 09:14 PM UTC
L
Natera 3Q Rev $794M >NTRA
Natera 3Q Rev $794M >NTRA
EQUITY | Nov 05, 2026, 09:06 PM UTC
L
Natera 3Q Loss/Shr 42c >NTRA
Natera 3Q Loss/Shr 42c >NTRA
EQUITY | Nov 05, 2026, 09:06 PM UTC
L
Form SCHEDULE 13G Natera, Inc. Filed by: FMR LLC
Filed on: November 5, 20
EQUITY | Nov 05, 2026, 06:23 PM UTC
M
Natera Q3'26 Results Expected Nov. 5; EPS Estimate Is (0.28) USD
Natera is scheduled to report Q3'26 results after the market close on Nov. 5. Revenue is estimated at 707.54 million USD and EPS at (0.28) USD.
EQUITY | Nov 04, 2026, 12:01 PM UTC
M
Natera to Report Third-Quarter Results on November 5, 2026
EQUITY | Oct 29, 2026, 12:03 PM UTC
M
Natera Shares Rise 2.4% After Announcing ctDNA Detection Advance
Natera said incorporating phased and structural variants enables ctDNA detection significantly below 1 part per 10 million, elevating molecular residual disease sensitivity.
EQUITY | Oct 19, 2026, 06:08 PM UTC
H
Natera Reports Q2 2026 Results: Full Earnings Call Transcript
On Thursday, Natera (NASDAQ: NTRA ) discussed second-quarter financial results during its earnings call. The full transcript is provided below. APIs provide real-time access to earnings call transcripts and financial dat
LIVE | Oct 12, 2026, 10:10 AM UTC
H
Natera, UnitedHealth Group And A Tech Stock On CNBC’s ‘Final Trades’
On CNBC’s “ Halftime Report Final Trades,” Rob Sechan, CEO of NewEdge Wealth, picked Hewlett Packard Enterprise Company (NYSE: HPE ). Supporting his choice, Hewlett Packard posted better-than-expected fiscal 2026 third-q
LIVE | Sep 28, 2026, 11:38 AM UTC
L
Natera Is Maintained at Outperform by RBC Capital
Ratings actions from Benzinga
NEWS | Sep 25, 2026, 02:05 PM UTC
L
RBC Capital maintains Outperform rating on Natera, $460 price target
RBC Capital maintained their Outperform rating on Natera's stock with a price target of $460.00.The price target implies an upside of 12.5% from the Sep 24 close of $408.79.Key takeaways from the analyst noteDominant Mar
EQUITY | Sep 25, 2026, 01:55 PM UTC
M
Natera shares jump after Japan approval for Signatera companion diagnostic
Natera said Japan’s Pharmaceuticals and Medical Devices Agency granted regulatory approval for Signatera as a companion diagnostic in muscle-invasive bladder cancer; the stock rose 5.2% in the afternoon session.
EQUITY | Sep 22, 2026, 07:44 PM UTC
M
Natera hits Japan regulatory approval milestone; Omeros reaches 5-year peak
Natera shares rose after Japan regulatory approval for its cancer test; Omeros shares gained after a Cantor Fitzgerald upgrade and optimism around its lead drug’s commercialization.
EQUITY | Sep 22, 2026, 05:51 PM UTC
M
Natera gets Japan PMDA authorization for Signatera in bladder cancer
Natera said Japan’s PMDA authorized its Signatera test as a companion diagnostic in muscle-invasive bladder cancer to guide adjuvant atezolizumab treatment.
REGULATION | Sep 22, 2026, 12:40 PM UTC
L
NTRA - Signatera™ Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer
NTRA - Signatera™ Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer
NEWS | Sep 22, 2026, 12:04 PM UTC
M
Natera Q1 revenue jumps; raises FY guidance; MRD patents upheld
Natera reported Q1 2026 revenue of $696.6M, raised full-year guidance to $2.74B–$2.82B, and won a court ruling upholding three MRD patents tied to a 30% ongoing royalty and preserved damages vs. Invitae. The update also
EQUITY | Sep 21, 2026, 11:28 AM UTC
L
NTRA - Largest MRD Study in Lung Cancer Highlights Strong Prognostic Value for SignateraTM
NTRA - Largest MRD Study in Lung Cancer Highlights Strong Prognostic Value for SignateraTM
NEWS | Sep 18, 2026, 10:09 AM UTC
M
Natera reports WCLC dataset of Signatera MRD in NSCLC
Natera announced WCLC data from 1,129 resected stage 1-3 NSCLC patients, saying Signatera MRD status predicts recurrence-free and overall survival in early post-surgical and surveillance settings.
EQUITY | Sep 18, 2026, 10:00 AM UTC
L
UBS raises Natera price target to $435
UBS raised Natera’s price target to $435.00 per share from $290.00 and maintained a Buy rating.
EQUITY | Sep 09, 2026, 06:04 PM UTC
L
Natera initiated at Buy by Rothschild & Co
Rothschild & Co initiated coverage on Natera with a Buy rating.
EQUITY | Sep 08, 2026, 12:32 PM UTC
L
NTRA publication cites strong clinical validation for Signatera MRD in lymphoma
TradeXchange Newsdesk says NTRA published findings supporting Signatera for MRD assessment in lymphoma.
EQUITY | Sep 01, 2026, 10:05 AM UTC
L
Natera publishes new clinical validation of Signatera for lymphoma MRD
Natera said new data published in Blood Neoplasia validates the prognostic and predictive value of Signatera for MRD assessment in newly diagnosed and relapsed/refractory lymphoma patients.
EQUITY | Sep 01, 2026, 10:00 AM UTC
L
Natera and Susan G. Komen announce national breast cancer partnership
Natera and Susan G. Komen® announced a national partnership to accelerate progress against breast cancer.
EQUITY | Aug 28, 2026, 03:06 PM UTC
L
Natera partners with Angiex for ctDNA monitoring in solid tumor trial
Natera partnered with Angiex to support ctDNA monitoring in a solid tumor trial using Signatera.
EQUITY | Aug 27, 2026, 11:11 AM UTC
L
Natera and Angiex partner to assess nuclear-delivered ADC with Signatera
Natera and Angiex will assess response to an investigational nuclear-delivered antibody-drug conjugate using Signatera.
EQUITY | Aug 27, 2026, 10:00 AM UTC
L
Natera Supports Clinical Trial
Natera is supporting a clinical trial assessing ctDNA dynamics with Latitude in advanced skin cancers
EQUITY | Aug 12, 2026, 10:02 AM UTC
H
Natera, Doximity, PubMatic, Airbnb And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Nasdaq Composite gaining around 1% on Friday. Shares of Natera Inc (NASDAQ: NTRA ) rose sharply after the company reported better-than-expected quarterly financial results and raised its
EARNINGS | Aug 07, 2026, 07:35 PM UTC
L
Natera CEO Says Company Is 'Clearly on a Roll' After Record Test Volumes, Raises Outlook
Natera Inc. (NASDAQ: NTRA ) stock surged Friday after the genetic testing company reported second-quarter results that topped Wall Street estimates and raised its full-year revenue outlook, supported by strong oncology d
EARNINGS | Aug 07, 2026, 06:35 PM UTC
H
JS&P 500 Hits Record As Jobs Shock Sinks Rate-Hike Bets: Stock Market Today
The S&P 500 cleared 7,755 and Wall Street is on course for its best week since April. The rally comes on the heels of a contraction in July payrolls. The U.S. economy unexpectedly shed 23,000 jobs in July against forecas
EARNINGS | Aug 07, 2026, 05:27 PM UTC
L
Natera Raises FY2026 Sales Guidance from $2.740B-$2.820B to $2.850B-$2.910B vs $2.797B Est
Natera (NASDAQ: NTRA ) raises FY2026 sales outlook from $2.740 billion-$2.820 billion to $2.850 billion-$2.910 billion vs $2.797 billion estimate.
EARNINGS | Aug 06, 2026, 08:17 PM UTC
M
Japan: Natera Submits Signatera For Approval
Natera submits Signatera for approval in Japan
EQUITY | Aug 05, 2026, 10:03 AM UTC
L
NTRA - Natera to Report its Second Quarter Results on August 6, 2026
NTRA - Natera to Report its Second Quarter Results on August 6, 2026
EARNINGS | Jul 30, 2026, 12:03 PM UTC
L
GH NTRA expert sees coverage tailwinds @ RBC
GH NTRA expert sees coverage tailwinds @ RBC
EQUITY | Jul 28, 2026, 11:09 AM UTC
L
NTRA Natera's Signatera MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study
NTRA Natera's Signatera MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study
EQUITY | Jul 22, 2026, 10:38 AM UTC
L
Tempus AI Makes Billion-Dollar Bet on the Future of Cancer Monitoring
On Monday, Tempus AI, Inc. (NASDAQ: TEM ) agreed to acquire Personalis, Inc. (NASDAQ: PSNL ), aiming to advance cancer monitoring through enhanced minimal residual disease (MRD) capabilities. Tempus AI shares erased earl
RATES | Jul 21, 2026, 06:52 PM UTC
H
Natera price target raised to $310 from $250 at Morgan Stanley
Morgan Stanley raised the firm's price target on Natera to $310 from $250 and keeps an Overweight rating on the shares. The firm is updating its model ahead of the earnings report.
EARNINGS | Jul 09, 2026, 10:59 AM UTC
L
Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer
Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer
EQUITY | Jul 06, 2026, 10:00 AM UTC
M
NTRA: Barclays Maintains Overweight
Barclays maintains overweight rating on Natera, lowers price target to $260
EQUITY | Jun 24, 2026, 02:55 PM UTC
M
NTRA Gets Japan Approval
NTRA's Signatera receives regulatory approval in Japan for colorectal cancer
EQUITY | Jun 24, 2026, 09:15 AM UTC
M
NTRA Wins Japan Approval
Natera's Signatera wins regulatory approval in Japan for colorectal cancer, with a commercial launch expected by year-end 2026
EQUITY | Jun 24, 2026, 07:52 AM UTC
M
NTRA: BTIG Raises PT
BTIG maintains buy rating on Natera and raises price target to $270
EQUITY | Jun 23, 2026, 08:05 PM UTC
M
NTRA Added to NCCN Guidelines
Natera's Signatera test is added to NCCN bladder cancer guidelines, strengthening its support in bladder cancer care
EQUITY | Jun 23, 2026, 10:06 AM UTC